All In Biotech

Drug Trial Radar · NCT06001788

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Phase 1 Study to Determine the Safety and Tolerability of Ziftomenib Combinations for the Treatment of KMT2A-rearranged or NPM1-mutant Relapsed/Refractory Acute Myeloid Leukemia

Last checked: Nov 21, 2026Latest source record: Aug 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

171

Planned (sponsor's estimate)

Start

Feb 22, 2024

Primary completion

Dec 2026

Study completion Aug 2027

Sponsor

Lead sponsor
Kura Oncology, Inc.Industry
Sponsor type
Industry
First posted
Aug 21, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The safety, tolerability, and antileukemic response of ziftomenib in combination with standard of care treatments for patients with relapsed/refractory acute myeloid leukemia will be examined with the following agents: FLAG-IDA, low-dose cytarabine, and gilteritinib.

Conditions

  • AML
  • AML With Mutated NPM1
  • Hematologic Malignancy
  • KMT2Ar
  • NPM1 Mutation
  • MLL Rearrangement
  • Leukemia
  • Acute Myeloid Leukemia
  • Leukemia, Myeloid
  • Leukemia, Myeloid, Acute
  • Acute Leukemia
  • Neoplasms by Histologic Type

Interventions

  • ZiftomenibDrug

    Oral administration

  • FludarabineDrug

    Intravenous infusion

  • IdarubicinDrug

    Intravenous infusion

  • CytarabineDrug

    Intravenous Infusion

  • GilteritinibDrug

    Oral administration

  • Granulocyte colony-stimulating factorBiological

    Subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of dose limiting toxicities (DLTs) per dose levelTime frame: During the first 28 days of ziftomenib in combination with SOC treatment (1 cycle)
  2. Descriptive statistics of adverse eventsTime frame: First dose of ziftomenib up to and including 28 days after last dose of ziftomenib, or if the patient is lost to follow-up, whichever comes first

Locations

45 sites in 3 countries. Site status is shown where the registry gives one.

  • Banner MD Anderson Cancer Center

    Gilbert, Arizona · Recruiting

  • USC Norris Comprehensive Cancer Center

    Los Angeles, California · Recruiting

  • UCLA Health - Bowyer Oncology Center

    Los Angeles, California · Recruiting

  • UC Irvine Health Chao Family Comprehensive Cancer Center

    Orange, California · Recruiting

  • University of California San Francisco

    San Francisco, California · Recruiting

  • Colorado Blood Cancer Institute

    Denver, Colorado · Recruiting

  • Smilow Cancer Hospital at Yale New Haven

    New Haven, Connecticut · Recruiting

  • Emory Healthcare - The Emory Clinic

    Atlanta, Georgia · Recruiting

  • Georgia Cancer Center at Augusta University

    Augusta, Georgia · Recruiting

  • Robert H. Lurie Comprehensive Cancer Center of Northwestern University

    Chicago, Illinois · Recruiting

  • Loyola University Medical Center

    Maywood, Illinois · Recruiting

  • Simmons Cancer Institute

    Springfield, Illinois · Withdrawn

  • University of Iowa Hospitals & Clinics

    Iowa City, Iowa · Recruiting

  • The University of Kansas Cancer Center

    Kansas City, Kansas · Recruiting

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts · Recruiting

  • Karmanos Cancer Institute

    Detroit, Michigan · Recruiting

  • Henry Ford Cancer Institute

    Detroit, Michigan · Recruiting

  • Washington University School of Medicine

    St Louis, Missouri · Recruiting

  • University of Nebraska Medical Center

    Omaha, Nebraska · Recruiting

  • John Theurer Cancer Center at Hackensack University Medical Center

    Hackensack, New Jersey · Recruiting

  • Roswell Park Comprehensive Cancer Center

    Buffalo, New York · Recruiting

  • Northwell Health, LLC PRIME

    Lake Success, New York · Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • Weill Cornell Medical College-NY Presbyterian Hospital

    New York, New York · Recruiting

  • Wilmot Cancer Institute, University of Rochester

    Rochester, New York · Recruiting

  • Stony Brook Cancer Center

    Stony Brook, New York · Recruiting

  • Atrium Health Levine Cancer Center

    Charlotte, North Carolina · Recruiting

  • UH Seidman Cancer Center

    Cleveland, Ohio · Recruiting

  • OU Health Stephenson Cancer Center

    Oklahoma City, Oklahoma · Recruiting

  • Lehigh Valley Topper Cancer Institute

    Allentown, Pennsylvania · Withdrawn

  • Prisma Health

    Greenville, South Carolina · Recruiting

  • Vanderbilt University Medical Center

    Nashville, Tennessee · Recruiting

  • Texas Oncology - Baylor Charles A. Sammons Cancer Center

    Dallas, Texas · Recruiting

  • MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • University of Vermont

    Burlington, Vermont · Recruiting

  • University of Virginia Comprehensive Cancer Center

    Charlottesville, Virginia · Recruiting

  • University of Washington

    Seattle, Washington · Recruiting

  • Froedtert & Medical College Clinics

    Milwaukee, Wisconsin · Recruiting

  • IRCCS Azienda Ospedaliero-Universitaria do Bologna - Policlinico di Sant'Orsola

    Bologna, Italy · Recruiting

  • Ospedale Santa Maria delle Croci

    Ravenna, Italy · Recruiting

Showing 40 of 45 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.